Gregory A Poland

List of Publications by Year
in descending order

401 papers	18,961 citations	13865 67 h-index	22161 113 g-index
416 all docs	416 docs citations	416 times ranked	20417 citing authors

#	Article	IF	Citations
1	Score Tests for Association between Traits and Haplotypes when Linkage Phase Is Ambiguous. American Journal of Human Genetics, 2002, 70, 425-434.	6.2	1,656
2	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, The, 2020, 396, 1595-1606.	13.7	511
3	Value of Immunological Markers in Predicting Responsiveness to Influenza Vaccination in Elderly Individuals. Journal of Virology, 2001, 75, 12182-12187.	3.4	376
4	Influenza vaccination of health care workers in hospitalsâ€"A review of studies on attitudes and predictors. Vaccine, 2009, 27, 3935-3944.	3.8	372
5	Immunosenescence and human vaccine immune responses. Immunity and Ageing, 2019, 16, 25.	4.2	323
6	Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel. JAMA - Journal of the American Medical Association, 2003, 289, 3283.	7.4	293
7	Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine, 2005, 23, 2251-2255.	3.8	248
8	Rubella. Lancet, The, 2015, 385, 2297-2307.	13.7	239
9	Prevention of Hepatitis B with the Hepatitis B Vaccine. New England Journal of Medicine, 2004, 351, 2832-2838.	27.0	229
10	Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 2001, 97, 3746-3754.	1.4	223
11	The Age-Old Struggle against the Antivaccinationists. New England Journal of Medicine, 2011, 364, 97-99.	27.0	202
12	Fine Mapping Causal Variants with an Approximate Bayesian Method Using Marginal Test Statistics. Genetics, 2015, 200, 719-736.	2.9	202
13	2009 H1N1 Influenza. Mayo Clinic Proceedings, 2010, 85, 64-76.	3.0	183
14	Revised SHEA Position Paper: Influenza Vaccination of Healthcare Personnel. Infection Control and Hospital Epidemiology, 2010, 31, 987-995.	1.8	178
15	The role of host genetics in the immune response to SARSâ€CoVâ€2 and COVIDâ€19 susceptibility and severity. Immunological Reviews, 2020, 296, 205-219.	6.0	175
16	Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine, 2001, 19, 2440-2445.	3.8	173
17	Immunosenescence: Role and measurement in influenza vaccine response among the elderly. Vaccine, 2007, 25, 3066-3069.	3.8	155
18	The weight of obesity on the human immune response to vaccination. Vaccine, 2015, 33, 4422-4429.	3.8	152

#	Article	IF	Citations
19	The 2009â€“2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns. Vaccine, 2010, 28, D3-D13.	3.8	143
20	Twin studies of immunogenicity â€" determining the genetic contribution to vaccine failure. Vaccine, 2001, 19, 2434-2439.	3.8	141
21	Determination of Deltoid Fat Pad Thickness. JAMA - Journal of the American Medical Association, 1997, 277, 1709.	7.4	140
22	Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: Preliminary results. Vaccine, 2008, 26, 1731-1736.	3.8	137
23	Personalized vaccines: the emerging field of vaccinomics. Expert Opinion on Biological Therapy, 2008, 8, 1659-1667.	3.1	134
24	Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine, 2003, 21, 4604-4608.	3.8	133
25	Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Review of Vaccines, 2012, 11, 985-994.	4.4	128
26	Development of vaccines against Zika virus. Lancet Infectious Diseases, The, 2018, 18, e211-e219.	9.1	125
27	Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine, 2011, 29, 9557-9562.	3.8	123
28	The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine, 2005, 23, 2078-2081.	3.8	118
29	Application of pharmacogenomics to vaccines. Pharmacogenomics, 2009, 10, 837-852.	1.3	113
30	Influenza Virus Resistance to Antiviral Agents: A Plea for Rational Use. Clinical Infectious Diseases, 2009, 48, 1254-1256.	5.8	113
31	Vaccinomics, adversomics, and the immune response network theory: Individualized vaccinology in the 21st century. Seminars in Immunology, 2013, 25, 89-103.	5.6	113
32	Vaccination policies for healthcare workers in Europe. Vaccine, 2014, 32, 4876-4880.	3.8	113
33	Prevalence and Morbidity of Undiagnosed Celiac Disease From aÂCommunity-Based Study. Gastroenterology, 2017, 152, 830-839.e5.	1.3	110
34	Fear, misinformation, and innumerates: How the Wakefield paper, the press, and advocacy groups damaged the public health. Vaccine, 2010, 28, 2361-2362.	3.8	108
35	Vaccines against Lyme Disease: What Happened and What Lessons Can We Learn?. Clinical Infectious Diseases, 2011, 52, s253-s258.	5.8	103
36	Systems biology approaches to new vaccine development. Current Opinion in Immunology, 2011, 23, 436-443.	5.5	97

#	Article	IF	Citations
37	SARS-CoV-2 Vaccine Development: Current Status. Mayo Clinic Proceedings, 2020, 95, 2172-2188.	3.0	96
38	Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine, 2001, 20, 430-438.	3.8	95
39	Trends affecting the future of vaccine development and delivery: The role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine, 2009, 27, 3240-3244.	3.8	93
40	The immunology of smallpox vaccines. Current Opinion in Immunology, 2009, 21, 314-320.	5.5	92
41	Immunogenetics of seasonal influenza vaccine response. Vaccine, 2008, 26, D35-D40.	3.8	91
42	Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months<subtitle>A Randomized Trial</subtitle>. JAMA - Journal of the American Medical Association, 2008, 300, 1532.	7.4	90
43	Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Human Genetics, 2010, 127, 207-221.	3.8	90
44	Vaccinomics and Personalized Vaccinology: Is Science Leading Us Toward a New Path of Directed Vaccine Development and Discovery?. PLoS Pathogens, 2011, 7, e1002344.	4.7	90
45	Secondary failure rates of measles vaccines: a metaanalysis of published studies. Pediatric Infectious Disease Journal, 1996, 15, 62-66.	2.0	90
46	Nanovaccinology: The next generation of vaccines meets 21st century materials science and engineering. Vaccine, 2012, 30, 6609-6611.	3.8	88
47	Influenza Vaccination Among Registered Nurses: Information Receipt, Knowledge, and Decision-Making at an Institution With a Multifaceted Educational Program. Infection Control and Hospital Epidemiology, 2008, 29, 99-106.	1.8	87
48	A systems biology approach to the effect of aging, immunosenescence and vaccine response. Current Opinion in Immunology, 2014, 29, 62-68.	5.5	87
49	Human Leukocyte Antigen Haplotypes in the Genetic Control of Immune Response to Measlesâ€Mumpsâ€Rubella Vaccine. Journal of Infectious Diseases, 2006, 193, 655-663.	4.0	86
50	Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. Experimental Gerontology, 2019, 124, 110632.	2.8	86
51	Avian and pandemic influenza: An overview. Vaccine, 2007, 25, 3057-3061.	3.8	85
52	Gender effects on humoral immune responses to smallpox vaccine. Vaccine, 2009, 27, 3319-3323.	3.8	85
53	The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Human Immunology, 2004, 65, 1506-1515.	2.4	83
54	Vaccinomics and a New Paradigm for the Development of Preventive Vaccines Against Viral Infections. OMICS A Journal of Integrative Biology, 2011, 15, 625-636.	2.0	82

#	Article	IF	Citations
55	The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Review of Vaccines, 2013, 12, 57-70.	4.4	82
56	Frequency of Measles Virus-Specific CD4 + and CD8 + T Cells in Subjects Seronegative or Highly Seropositive for Measles Vaccine. Vaccine Journal, 2003, 10, 411-416.	3.1	81
57	Measles virus receptors: SLAM and CD46. Reviews in Medical Virology, 2004, 14, 217-229.	8.3	81
58	Genome-wide association study of antibody response to smallpox vaccine. Vaccine, 2012, 30, 4182-4189.	3.8	80
59	Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome. Scientific Reports, 2020, 10, 14179.	3.3	80
60	Influenza immunization and COVID-19. Vaccine, 2020, 38, 6078-6079.	3.8	79
61	Vaccines against Avian Influenza â€" A Race against Time. New England Journal of Medicine, 2006, 354, 1411-1413.	27.0	77
62	Personalized vaccinology: One size and dose might not fit both sexes. Vaccine, 2013, 31, 2599-2600.	3.8	77
63	Vaccinating Health Care Workers Against Influenza: The Ethical and Legal Rationale for a Mandate. American Journal of Public Health, 2011, 101, 212-216.	2.7	76
64	Prevention of Lyme Disease: A Review of the Evidence. Mayo Clinic Proceedings, 2001, 76, 713-724.	3.0	75
65	Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients. Human Genetics, 2012, 131, 1403-1421.	3.8	75
66	The Impact of Immunosenescence on Humoral Immune Response Variation after Influenza A/H1N1 Vaccination in Older Subjects. PLoS ONE, 2015, 10, e0122282.	2.5	74
67	Associations between Measles Vaccine Immunity and Singleâ€Nucleotide Polymorphisms in Cytokine and Cytokine Receptor Genes. Journal of Infectious Diseases, 2007, 195, 21-29.	4.0	73
68	A taxonomy of reasoning flaws in the anti-vaccine movement. Vaccine, 2007, 25, 3146-3152.	3.8	73
69	Human Leukocyte Antigen and Cytokine Receptor Gene Polymorphisms Associated With Heterogeneous Immune Responses to Mumps Viral Vaccine. Pediatrics, 2008, 121, e1091-e1099.	2.1	72
70	Measles, Mumps, and Rubella. Clinical Obstetrics and Gynecology, 2012, 55, 550-559.	1.1	71
71	Zika Vaccine Development: Current Status. Mayo Clinic Proceedings, 2019, 94, 2572-2586.	3.0	69
72	Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial. Mayo Clinic Proceedings, 2005, 80, 601-610.	3.0	68

#	Article	IF	Citations
73	Influenza Vaccines: From Surveillance Through Production to Protection. Mayo Clinic Proceedings, 2010, 85, 257-273.	3.0	66
74	A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine, 2011, 29, 4485-4491.	3.8	66
75	Adversomics: The Emerging Field of Vaccine Adverse Event Immunogenetics. Pediatric Infectious Disease Journal, 2009, 28, 431-432.	2.0	65
76	Genetic polymorphisms in host antiviral genes: Associations with humoral and cellular immunity to measles vaccine. Vaccine, 2011, 29, 8988-8997.	3.8	64
77	Taxa of the Nasal Microbiome Are Associated with Influenza-Specific IgA Response to Live Attenuated Influenza Vaccine. PLoS ONE, 2016, 11, e0162803.	2.5	64
78	Human Leukocyte Antigen Class II Alleles and Rubellaâ€Specific Humoral and Cellâ€Mediated Immunity following Measlesâ€Mumpsâ€Rubellaâ€"II Vaccination. Journal of Infectious Diseases, 2005, 191, 515-519.	4.0	63
79	HLA supertypes and immune responses to measlesâ€"mumpsâ€"rubella viral vaccine: Findings and implications for vaccine design. Vaccine, 2007, 25, 3090-3100.	3.8	63
80	Vaccine immunogenetics: Bedside to bench to population. Vaccine, 2008, 26, 6183-6188.	3.8	63
81	Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine, 2021, 39, 457-459.	3.8	63
82	Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine, 2011, 29, 7883-7895.	3.8	62
83	Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine, 2014, 32, 1946-1953.	3.8	62
84	Variations in measles vaccineâ€"specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. Journal of Allergy and Clinical Immunology, 2007, 120, 666-672.	2.9	61
85	Associations Between Demographic Variables and Multiple Measles-Specific Innate and Cell-Mediated Immune Responses After Measles Vaccination. Viral Immunology, 2012, 25, 29-36.	1.3	61
86	The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Human Genetics, 2011, 130, 547-61.	3.8	60
87	Leptin and leptin-related gene polymorphisms, obesity, and influenza A/H1N1 vaccine-induced immune responses in older individuals. Vaccine, 2014, 32, 881-887.	3.8	60
88	The genetic basis for variation in antibody response to vaccines. Current Opinion in Pediatrics, 1998, 10, 208-215.	2.0	59
89	Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine, 2001, 20, 22-30.	3.8	59
90	Hepatitis B Vaccine Nonresponse and Celiac Disease. American Journal of Gastroenterology, 2003, 98, 2289-2292.	0.4	59

#	Article	IF	Citations
91	Variation in vaccine response in normal populations. Pharmacogenomics, 2004, 5, 417-427.	1.3	59
92	Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. Human Genetics, 2017, 136, 421-435.	3.8	59
93	TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer riskâ˜†. Gynecologic Oncology, 2003, 88, 326-332.	1.4	58
94	Polymorphisms in the Vitamin A Receptor and Innate Immunity Genes Influence the Antibody Response to Rubella Vaccination. Journal of Infectious Diseases, 2010, 201, 207-213.	4.0	58
95	The Association of CD46, SLAM and CD209 Cellular Receptor Gene SNPs with Variations in Measles Vaccine-Induced Immune Responses: A Replication Study and Examination of Novel Polymorphisms. Human Heredity, 2011, 72, 206-223.	0.8	58
96	Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine, 2001, 19, 2428-2433.	3.8	57
97	Facing the challenges of influenza in healthcare settings: The ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine, 2008, 26, D27-D30.	3.8	57
98	Sex Differences in Older Adults' Immune Responses to Seasonal Influenza Vaccination. Frontiers in Immunology, 2019, 10, 180.	4.8	57
99	Cytokine production patterns and antibody response to measles vaccine. Vaccine, 2003, 21, 3946-3953.	3.8	56
100	Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines. Clinical Infectious Diseases, 2010, 50, S45-S53.	5.8	55
101	Single-dose Oxfordâ€"AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet, The, 2021, 397, 854-855.	13.7	55
102	The association of class I HLA alleles and antibody levels after a single dose of measles vaccine. Human Immunology, 2003, 64, 103-109.	2.4	53
103	Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine, 2004, 22, 1914-1920.	3.8	53
104	System-Wide Associations between DNA-Methylation, Gene Expression, and Humoral Immune Response to Influenza Vaccination. PLoS ONE, 2016, 11, e0152034.	2.5	53
105	Measles Reimmunization in Children Seronegative After Initial Immunization. JAMA - Journal of the American Medical Association, 1997, 277, 1156.	7.4	52
106	Immunization of Health-Care Providers: Necessity and Public Health Policies. Healthcare (Switzerland), 2016, 4, 47.	2.0	52
107	A global agenda for older adult immunization in the COVID-19 era: A roadmap for action. Vaccine, 2021, 39, 5240-5250.	3.8	52
108	HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics, 2005, 56, 798-807.	2.4	51

#	Article	IF	Citations
109	Vaccine education spectrum disorder: the importance of incorporating psychological and cognitive models into vaccine education. Vaccine, 2011, 29, 6145-6148.	3.8	51
110	Variability in Humoral Immunity to Measles Vaccine: New Developments. Trends in Molecular Medicine, 2015, 21, 789-801.	6.7	51
111	Smallpox vaccines for biodefense. Vaccine, 2009, 27, D73-D79.	3.8	50
112	Statistical Methods for Testing Genetic Pleiotropy. Genetics, 2016, 204, 483-497.	2.9	50
113	Receptivity to Mandatory Influenza Vaccination Policies for Healthcare Workers Among Registered Nurses Working on Inpatient Units. Infection Control and Hospital Epidemiology, 2008, 29, 170-173.	1.8	49
114	Vaccinomics: Current Findings, Challenges and Novel Approaches for Vaccine Development. AAPS Journal, 2011, 13, 438-444.	4.4	49
115	Development of a Novel Efficient Fluorescence-Based Plaque Reduction Microneutralization Assay for Measles Virus Immunity. Vaccine Journal, 2008, 15, 1054-1059.	3.1	48
116	Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Human Immunology, 2013, 74, 1263-1266.	2.4	48
117	Adversomics: a new paradigm for vaccine safety and design. Expert Review of Vaccines, 2015, 14, 935-947.	4.4	48
118	Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects1. Vaccine, 1999, 17, 1525-1531.	3.8	47
119	Genome-wide genetic associations with IFNÎ³ response to smallpox vaccine. Human Genetics, 2012, 131, 1433-1451.	3.8	47
120	Current Challenges in Vaccinology. Frontiers in Immunology, 2020, 11, 1181.	4.8	47
121	The clinicianâ€™s guide to the anti-vaccinationistsâ€™ galaxy. Human Immunology, 2012, 73, 859-866.	2.4	46
122	Flu Myths: Dispelling the Myths Associated With Live Attenuated Influenza Vaccine. Mayo Clinic Proceedings, 2008, 83, 77-84.	3.0	45
123	Replication of rubella vaccine population genetic studies: Validation of HLA genotype and humoral response associations. Vaccine, 2009, 27, 6926-6931.	3.8	45
124	SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics, 2010, 62, 197-210.	2.4	45
125	2â€²-5â€²-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Human Immunology, 2010, 71, 383-391.	2.4	45
126	Polymorphisms in HLA-DPB1 Are Associated With Differences in Rubella Virus-Specific Humoral Immunity After Vaccination. Journal of Infectious Diseases, 2015, 211, 898-905.	4.0	45

#	Article	IF	Citations
127	Variability in Immune Response to Pathogens: Using Measles Vaccine to Probe Immunogenetic Determinants of Response. American Journal of Human Genetics, 1998, 62, 215-220.	6.2	44
128	Monitoring the Safety of a Smallpox Vaccination Program in the United States: Report of the Joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board. Clinical Infectious Diseases, 2008, 46, S258-S270.	5.8	44
129	The re-emergence of measles in developed countries: Time to develop the next-generation measles vaccines?. Vaccine, 2012, 30, 103-104.	3.8	44
130	Consistency of HLA associations between two independent measles vaccine cohorts: A replication study. Vaccine, 2012, 30, 2146-2152.	3.8	44
131	â€œLet there be lightâ€• the role of vitamin D in the immune response to vaccines. Expert Review of Vaccines, 2015, 14, 1427-1440.	4.4	44
132	Science, medicine, and the future: New vaccine development. BMJ: British Medical Journal, 2002, 324, 1315-1319.	2.3	43
133	Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine, 2009, 28, 38-47.	3.8	43
134	Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Review of Vaccines, 2010, 9, 1127-1133.	4.4	43
135	Heme oxygenaseâ€1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB Journal, 2012, 26, 2911-2918.	0.5	43
136	The prevention of Lyme disease with vaccine. Vaccine, 2001, 19, 2303-2308.	3.8	42
137	The Top Five â€œGame Changersâ€•in Vaccinology: Toward Rational and Directed Vaccine Development. OMICS A Journal of Integrative Biology, 2011, 15, 533-537.	2.0	42
138	Technical and biological variance structure in mRNA-Seq data: life in the real world. BMC Genomics, 2012, 13, 304.	2.8	42
139	Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development. Vaccine, 2020, 38, 4219-4220.	3.8	41
140	Failure to Reach the Goal of Measles Elimination. Archives of Internal Medicine, 1994, 154, 1815.	3.8	40
141	Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine, 2001, 19, 2216-2220.	3.8	40
142	Associations between Human Leukocyte Antigen Homozygosity and Antibody Levels to Measles Vaccine. Journal of Infectious Diseases, 2002, 185, 1545-1549.	4.0	40
143	Effect of Multiple Freeze-Thaw Cycles on Detection of Measles, Mumps, and Rubella Virus Antibodies. Vaccine Journal, 2003, 10, 19-21.	3.1	40
144	Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunology, 2010, 11, 48.	2.2	40

#	Article	IF	Citations
145	Mandating influenza vaccination for health care workers: Putting patients and professional ethics over personal preference. Vaccine, 2010, 28, 5757-5759.	3.8	40
146	Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination. Frontiers in Immunology, 2016, 7, 450.	4.8	40
147	Smallpox and Vaccinia. , 2018, , 1001-1030.e12.		40
148	Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine, 2022, 40, 183-186.	3.8	40
149	Influenza Immunization of Schoolchildren: Can We Interrupt Community Epidemics?. Pediatrics, 1999, 103, 1280-1281.	2.1	39
150	Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals. Vaccine, 2016, 34, 3993-4002.	3.8	39
151	Influenza vaccine failure: failure to protect or failure to understand?. Expert Review of Vaccines, 2018, 17, 495-502.	4.4	39
152	Differential durability of immune responses to measles and mumps following MMR vaccination. Vaccine, 2019, 37, 1775-1784.	3.8	39
153	Current perspectives in assessing humoral immunity after measles vaccination. Expert Review of Vaccines, 2019, 18, 75-87.	4.4	39
154	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine, 2021, 39, 6111-6116.	3.8	39
155	The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine, 1999, 17, 1674-1679.	3.8	38
156	Effects of vitamin A and D receptor gene polymorphisms/haplotypes on immune responses to measles vaccine. Pharmacogenetics and Genomics, 2012, 22, 20-31.	1.5	38
157	Defending against smallpox: a focus on vaccines. Expert Review of Vaccines, 2016, 15, 1197-1211.	4.4	38
158	The development of COVID-19 vaccines in the United States: Why and how so fast?. Vaccine, 2021, 39, 2491-2495.	3.8	38
159	Immunologic significance of HLA class I genes in measles virus-specific IFN-Î³ and IL-4 cytokine immune responses. Immunogenetics, 2005, 57, 828-836.	2.4	37
160	Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiology, 2010, 5, 1757-1760.	2.0	37
161	Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers. Human Vaccines and Immunotherapeutics, 2015, 11, 961-969.	3.3	37
162	Relationship of HLA-DQAI alleles and humoral antibody following measles vaccination. International Journal of Infectious Diseases, 1998, 2, 143-146.	3.3	36

#	Article	IF	Citations
163	Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines. Expert Review of Vaccines, 2006, 5, 33-43.	4.4	34
164	Common SNPs/Haplotypes in IL18R1 and IL18 Genes Are Associated With Variations in Humoral Immunity to Smallpox Vaccination in Caucasians and African Americans. Journal of Infectious Diseases, 2011, 204, 433-441.	4.0	34
165	Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene, 2012, 510, 59-65.	2.2	34
166	Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics, 2014, 66, 493-499.	2.4	34
167	Transcriptomic signatures of cellular and humoral immune responses in older adults after seasonal influenza vaccination identified by data-driven clustering. Scientific Reports, 2018, 8, 739.	3.3	34
168	Extended LTA, TNF, LST1 and HLA Gene Haplotypes and Their Association with Rubella Vaccine-Induced Immunity. PLoS ONE, 2010, 5, e11806.	2.5	34
169	Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. Vaccine, 2012, 30, 2159-2167.	3.8	33
170	Genome-Wide Characterization of Transcriptional Patterns in High and Low Antibody Responders to Rubella Vaccination. PLoS ONE, 2013, 8, e62149.	2.5	33
171	Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study. Vaccine, 2021, 39, 2605-2607.	3.8	33
172	The role of mass spectrometry in vaccine development. Vaccine, 2001, 19, 2692-2700.	3.8	32
173	Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clinical Immunology, 2005, 115, 154-161.	3.2	32
174	Healthcare Workers' Perceptions of Mandatory Vaccination: Results of an Anonymous Survey in a German University Hospital. Infection Control and Hospital Epidemiology, 2010, 31, 1066-1069.	1.8	32
175	Granzyme B ELISPOT assay to measure influenza-specific cellular immunity. Journal of Immunological Methods, 2013, 398-399, 44-50.	1.4	32
176	Identification and Characterization of Novel, Naturally Processed Measles Virus Class II HLA-DRB1 Peptides. Journal of Virology, 2004, 78, 42-51.	3.4	31
177	Relationship between HLA Polymorphisms and Gamma Interferon and Interleukin-10 Cytokine Production in Healthy Individuals after Rubella Vaccination. Vaccine Journal, 2007, 14, 115-122.	3.1	31
178	Emerging vaccines for influenza. Expert Opinion on Emerging Drugs, 2008, 13, 21-40.	2.4	31
179	Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine, 2009, 27, 3359-3366.	3.8	31
180	A global prescription for adult immunization: Time is catching up with us. Vaccine, 2010, 28, 7137-7139.	3.8	31

#	Article	IF	Citations
181	Human Leukocyte Antigen Genotypes in the Genetic Control of Adaptive Immune Responses to Smallpox Vaccine. Journal of Infectious Diseases, 2011, 203, 1546-1555.	4.0	31
182	Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine, 1999, 17, 1719-1725.	3.8	30
183	T-Cell epitope discovery for variola and vaccinia viruses. Reviews in Medical Virology, 2007, 17, 93-113.	8.3	30
184	Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. Virology, 2003, 312, 495-506.	2.4	29
185	Childhood asthma and measles vaccine response. Annals of Allergy, Asthma and Immunology, 2006, 97, 469-476.	1.0	29
186	Integration of Immune Cell Populations, mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination: Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations. Frontiers in Immunology, 2017, 8, 445.	4.8	29
187	Parameters potentially affecting interpretation of immunogenicity and efficacy data in vaccine trials: are they adequately reported?. Vaccine, 1996, 14, 25-27.	3.8	28
188	Assessment of humoral and cell-mediated immune response to measlesâ€mumpsâ€rubella vaccine viruses among patients with asthma. Allergy and Asthma Proceedings, 2010, 31, 499-506.	2.2	28
189	Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees. Cytokine, 2010, 50, 24-29.	3.2	28
190	Vaccinology in the third millennium: scientific and social challenges. Current Opinion in Virology, 2016, 17, 116-125.	5.4	28
191	High-Dimensional Gene Expression Profiling Studies in High and Low Responders to Primary Smallpox Vaccination. Journal of Infectious Diseases, 2012, 206, 1512-1520.	4.0	27
192	ReliefSeq: A Gene-Wise Adaptive-K Nearest-Neighbor Feature Selection Tool for Finding Gene-Gene Interactions and Main Effects in mRNA-Seq Gene Expression Data. PLoS ONE, 2013, 8, e81527.	2.5	27
193	HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study. Human Genetics, 2014, 133, 1083-1092.	3.8	27
194	Identification of Class II HLA-DRB1*03-Bound Measles Virus Peptides by 2D-Liquid Chromatography Tandem Mass Spectrometry. Journal of Proteome Research, 2005, 4, 2243-2249.	3.7	26
195	Extinction of the Human Leukocyte Antigen Homozygosity Effect After Two Doses of the Measles-Mumps-Rubella Vaccine. Human Immunology, 2005, 66, 788-798.	2.4	26
196	Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination. Human Genetics, 2014, 133, 1407-1417.	3.8	26
197	The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine, 2021, 39, 1122-1130.	3.8	26
198	Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine, 1999, 17, 2779-2785.	3.8	25

#	Article	IF	Citations
199	Interleukin-4 induced by measles virus and measles-derived peptides as measured by IL-4 receptor-blocking ELISA. Journal of Immunological Methods, 2004, 287, 217-225.	1.4	25
200	MMR Vaccine and Autism: Vaccine Nihilism and Postmodern Science. Mayo Clinic Proceedings, 2011, 86, 869-871.	3.0	25
201	Detection of Influenza A/H1N1-Specific Human IgG-Secreting B Cells in Older Adults by ELISPOT Assay. Viral Immunology, 2014, 27, 32-38.	1.3	25
202	Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine, 2014, 32, 3548-3554.	3.8	25
203	Gene signatures related to HAI response following influenza A/H1N1 vaccine in older individuals. Heliyon, 2016, 2, e00098.	3.2	25
204	Factors and considerations for establishing and improving seasonal influenza vaccination of health workers: Report from a WHO meeting, January 16â€“17, Berlin, Germany. Vaccine, 2019, 37, 6255-6261.	3.8	25
205	The Prevention of Pneumococcal Disease by Vaccines: Promises and Challenges. Infectious Disease Clinics of North America, 2001, 15, 97-122.	5.1	24
206	If You Could Halve the Mortality Rate, Would You Do It?. Clinical Infectious Diseases, 2002, 35, 378-380.	5.8	24
207	Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. Journal of the American Society for Mass Spectrometry, 2005, 16, 1812-1817.	2.8	24
208	A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed. Vaccine, 2012, 30, 4778-4784.	3.8	24
209	Associations between polymorphisms in the antiviral TRIM genes and measles vaccine immunity. Human Immunology, 2013, 74, 768-774.	2.4	24
210	High-Throughput Assay Optimization and Statistical Interpolation of Rubella-Specific Neutralizing Antibody Titers. Vaccine Journal, 2014, 21, 340-346.	3.1	24
211	Lessons learned in the analysis of high-dimensional data in vaccinomics. Vaccine, 2015, 33, 5262-5270.	3.8	24
212	Emerging Mumps Infection. Pediatric Infectious Disease Journal, 2016, 35, 799-801.	2.0	24
213	Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination. Vaccine, 2016, 34, 4913-4919.	3.8	24
214	Utility of a â€œSwish and Spitâ€•Technique for the Collection of Buccal Cells for TAP Haplotype Determination. Mayo Clinic Proceedings, 1995, 70, 951-954.	3.0	23
215	Smallpox vaccines: Current and future. Translational Research, 2003, 142, 252-257.	2.3	23
216	Vaccinomics and bioinformatics: Accelerants for the next golden age of vaccinology. Vaccine, 2010, 28, 3509-3510.	3.8	23

#	Article	IF	Citations
217	Pertussis outbreaks and pertussis vaccines: New insights, new concerns, new recommendations?. Vaccine, 2012, 30, 6957-6959.	3.8	23
218	Turkey Versus Guinea Pig Red Blood Cells: Hemagglutination Differences Alter Hemagglutination Inhibition Responses Against Influenza A/H1N1. Viral Immunology, 2014, 27, 174-178.	1.3	23
219	SARS-CoV-2: a time for clear and immediate action. Lancet Infectious Diseases, The, 2020, 20, 531-532.	9.1	23
220	A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade. Viruses, 2020, 12, 1186.	3.3	23
221	Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities. Lancet Infectious Diseases, The, 2021, 21, e342-e347.	9.1	23
222	A large population-based association study between HLA and KIR genotypes and measles vaccine antibody responses. PLoS ONE, 2017, 12, e0171261.	2.5	23
223	A maternal immunization program (MIP): Developing a schedule and platform for routine immunization during pregnancy. Vaccine, 2011, 29, 9411-9413.	3.8	22
224	Human Leukocyte Antigens and Cellular Immune Responses to Anthrax Vaccine Adsorbed. Infection and Immunity, 2013, 81, 2584-2591.	2.2	22
225	Smallpox vaccine: problems and prospects. Immunology and Allergy Clinics of North America, 2003, 23, 731-743.	1.9	21
226	Studies of twins in vaccinology. Vaccine, 2007, 25, 3160-3164.	3.8	21
227	Statistical Approach To Estimate Vaccinia-Specific Neutralizing Antibody Titers Using a High-Throughput Assay. Vaccine Journal, 2009, 16, 1105-1112.	3.1	21
228	Leptin-based adjuvants: An innovative approach to improve vaccine response. Vaccine, 2013, 31, 1666-1672.	3.8	21
229	Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virusâ€"Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. Journal of Infectious Diseases, 2018, 217, 560-566.	4.0	21
230	Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination. PLoS ONE, 2018, 13, e0191812.	2.5	21
231	Avian influenza vaccines: what's all the flap?. Lancet, The, 2006, 367, 1636-1638.	13.7	20
232	Human leukocyte antigen and interleukin 2, 10 and 12p40 cytokine responses to measles: Is there evidence of the HLA effect?. Cytokine, 2006, 36, 173-179.	3.2	20
233	Response surface methodology to determine optimal cytokine responses in human peripheral blood mononuclear cells after smallpox vaccination. Journal of Immunological Methods, 2009, 341, 97-105.	1.4	20
234	Next-generation sequencing: a transformative tool for vaccinology. Expert Review of Vaccines, 2009, 8, 963-967.	4.4	20

#	Article	IF	Citations
235	Personal Choice or Evidence-Based Nursing Intervention: Nurses' Decision-Making about Influenza Vaccination. Worldviews on Evidence-Based Nursing, 2010, 7, 111-20.	2.9	20
236	Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts. Immunologic Research, 2014, 58, 1-8.	2.9	20
237	Single nucleotide polymorphisms/haplotypes associated with multiple rubella-specific immune response outcomes post-MMR immunization in healthy children. Immunogenetics, 2015, 67, 547-561.	2.4	20
238	Whole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor Genes Associated with Measles-Specific Antibody Response after Vaccination. PLoS ONE, 2016, 11, e0160970.	2.5	20
239	Vaccine Safety: Injecting a Dose of Common Sense. Mayo Clinic Proceedings, 2000, 75, 135-139.	3.0	19
240	Detection of Measles Virus-Specific Interferon-Î³-Secreting T-Cells by ELISPOT. , 2005, 302, 207-218.		19
241	Evaluating existing recommendations for hepatitis A and B vaccination. American Journal of Medicine, 2005, 118, 16-20.	1.5	19
242	Mandating influenza vaccination for healthcare workers. Expert Review of Vaccines, 2009, 8, 1469-1474.	4.4	19
243	The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins. Virology, 2010, 408, 232-240.	2.4	19
244	Single-nucleotide polymorphism associations in common with immune responses to measles and rubella vaccines. Immunogenetics, 2014, 66, 663-669.	2.4	19
245	The personal touch: strategies toward personalized vaccines and predicting immune responses to them. Expert Review of Vaccines, 2014, 13, 657-669.	4.4	19
246	The composition of immune cells serves as a predictor of adaptive immunity in a cohort of 50â€•to 74â€•yearâ€•old adults. Immunology, 2016, 148, 266-275.	4.4	19
247	HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine, 2009, 27, 3349-3358.	3.8	18
248	Genetic Variation in IL18R1 and IL18 Genes and Inteferon Î³ ELISPOT Response to Smallpox Vaccination: An Unexpected Relationship. Journal of Infectious Diseases, 2013, 208, 1422-1430.	4.0	18
249	Cytokine production associated with smallpox vaccine responses. Immunotherapy, 2014, 6, 1097-1112.	2.0	18
250	HLA genotypes and rubella vaccine immune response: Additional evidence. Vaccine, 2014, 32, 4206-4213.	3.8	18
251	Strategies to maximize influenza vaccine impact in older adults. Vaccine, 2018, 36, 5940-5948.	3.8	18
252	The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines. Expert Review of Vaccines, 2019, 18, 253-267.	4.4	18

#	Article	IF	Citations
253	Associations between Single Nucleotide Polymorphisms in Cellular Viral Receptors and Attachment Factor-Related Genes and Humoral Immunity to Rubella Vaccination. PLoS ONE, 2014, 9, e99997.	2.5	18
254	Vaccidents and adversomics. Vaccine, 2010, 28, 6549-6550.	3.8	17
255	Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: Persistence, dampening, and extinction of associations found after a first dose. Vaccine, 2011, 29, 7982-7991.	3.8	17
256	RITAN: rapid integration of term annotation and network resources. PeerJ, 2019, 7, e6994.	2.0	17
257	Seroprevalence and durability of rubella virus antibodies in a highly immunized population. Vaccine, 2019, 37, 3876-3882.	3.8	17
258	Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. Journal of Infectious Diseases, 2022, 226, 23-31.	4.0	17
259	Structured clinical teaching strategy. Medical Teacher, 1991, 13, 177-184.	1.8	16
260	HLA homozygosity does not adversely affect measles vaccine-induced cytokine responses. Virology, 2007, 364, 87-94.	2.4	16
261	Increasing Influenza Vaccination Rates: The Need to Vaccinate Throughout the Entire Influenza Season. American Journal of Medicine, 2008, 121, S3-S10.	1.5	16
262	Correlations Between Vaccinia-Specific Immune Responses Within a Cohort of Armed Forces Members. Viral Immunology, 2011, 24, 415-420.	1.3	16
263	Attitudes toward and Uptake of H1N1 Vaccine among Health Care Workers during the 2009 H1N1 Pandemic. PLoS ONE, 2011, 6, e29478.	2.5	16
264	Influenza vaccine, Guillainâ€"BarrÃ© syndrome, and chasing zero. Vaccine, 2012, 30, 5801-5803.	3.8	16
265	Asthma Status and Waning of Measles Antibody Concentrations after Measles Immunization. Pediatric Infectious Disease Journal, 2014, 33, 1016-1022.	2.0	16
266	Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients. Vaccine, 2016, 34, 3283-3290.	3.8	16
267	Vitamin D, leptin and impact on immune response to seasonal influenza A/H1N1 vaccine in older persons. Human Vaccines and Immunotherapeutics, 2016, 12, 691-698.	3.3	16
268	Detection of Vaccinia Virus-Specific IFNÎ³ and IL-10 Secretion from Human PBMCs and CD8+ T Cells by ELISPOT. Methods in Molecular Biology, 2012, 792, 199-218.	0.9	16
269	Universal Vaccination of Healthy Children Against Influenza. Paediatric Drugs, 2002, 4, 65-71.	3.1	15
270	Correlation Between Rubella Antibody Levels and Cytokine Measures of Cell-Mediated Immunity. Viral Immunology, 2009, 22, 451-456.	1.3	15

#	Article	IF	Citations
271	New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. Vaccine, 2013, 31, A1-A20.	3.8	15
272	Soft truncation thresholding for gene set analysis of RNA-seq data: Application to a vaccine study. Scientific Reports, 2013, 3, 2898.	3.3	15
273	Polymorphisms in STING Affect Human Innate Immune Responses to Poxviruses. Frontiers in Immunology, 2020, 11, 567348.	4.8	15
274	Vaccines against Influenza A (H5N1): Evidence of Progress. Journal of Infectious Diseases, 2008, 198, 629-631.	4.0	14
275	Health and Safety. American Journal of Nursing, 2008, 108, 32-34.	0.4	14
276	Differential cellular immune responses to wildâ€type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene. Journal of Medical Virology, 2010, 82, 1966-1975.	5.0	14
277	Developing vaccine policy: Attributes of â€œjust policyâ€•and a proposed template to guide decision and policy making. Vaccine, 2011, 29, 7577-7578.	3.8	14
278	SNPPicker: High quality tag SNP selection across multiple populations. BMC Bioinformatics, 2011, 12, 129.	2.6	14
279	Independence of measles-specific humoral and cellular immune responses to vaccination. Human Immunology, 2012, 73, 474-479.	2.4	14
280	Measles and mumps outbreaks in the United States: Think globally, vaccinate locally. Vaccine, 2014, 32, 4703-4704.	3.8	14
281	Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age. Vaccine, 2020, 38, 1249-1257.	3.8	14
282	Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design. Vaccine, 2021, 39, 1547-1550.	3.8	14
283	The need for broadly protective COVID-19 vaccines: Beyond S-only approaches. Vaccine, 2021, 39, 4239-4241.	3.8	14
284	Smallpox vaccines: from first to second to third generation. Lancet, The, 2005, 365, 362-363.	13.7	14
285	Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents. Clinical Immunology, 2022, 234, 108912.	3.2	14
286	Isolation and rapid identification of an abundant self-peptide from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection. Journal of Immunological Methods, 2000, 246, 1-12.	1.4	13
287	Association of Parental Vaccination Reports With Measles, Mumps, and Rubella Protective Antibody Levels: Comparison of Somali Immigrant, Hispanic Migrant, and US Children in Rochester, Minn. Mayo Clinic Proceedings, 2002, 77, 241-245.	3.0	13
288	Effect of human leukocyte antigen homozygosity on rubella vaccineâ€“induced humoral and cell-mediated immune responses. Human Immunology, 2010, 71, 128-135.	2.4	13

#	Article	IF	Citations
289	Improving the public health: The U.S. recommendation for universal influenza immunization. Vaccine, 2010, 28, 2799-2800.	3.8	13
290	Statistical modeling using early markers of innate immunity to explain variation in humoral responses to influenza vaccine in older adults. Vaccine, 2015, 33, 3682-3688.	3.8	13
291	Another emerging arbovirus, another emerging vaccine: Targeting Zika virus. Vaccine, 2016, 34, 2291-2293.	3.8	13
292	Heritability of vaccine-induced measles neutralizing antibody titers. Vaccine, 2017, 35, 1390-1394.	3.8	13
293	Immunization education for internal medicine residents: A cluster-randomized controlled trial. Vaccine, 2018, 36, 1823-1829.	3.8	13
294	Correlations between measles, mumps, and rubella serum antibody levels in Olmsted County school children. Vaccine, 2001, 19, 1363-1368.	3.8	12
295	Identification of Th0 cells responding to measles virus. Human Immunology, 2005, 66, 104-115.	2.4	12
296	Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes. Human Immunology, 2012, 73, 636-640.	2.4	12
297	Writing a scientific paperâ€"A brief guide for new investigators. Vaccine, 2017, 35, 722-728.	3.8	12
298	Immunization of healthcare personnel in Europe: Time to move forward with a common program. Vaccine, 2020, 38, 3187-3190.	3.8	12
299	Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides. Vaccine, 2006, 24, 5381-5389.	3.8	11
300	Common Cold, Uncommon Variation. New England Journal of Medicine, 2009, 360, 2245-2246.	27.0	11
301	Genetic basis for variation of vaccine response: our studies with rubella vaccine. Paediatrics and Child Health (United Kingdom), 2009, 19, S156-S159.	0.4	11
302	Profiling of Measles-Specific Humoral Immunity in Individuals Following Two Doses of MMR Vaccine Using Proteome Microarrays. Viruses, 2015, 7, 1113-1133.	3.3	11
303	Literatureâ€based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses. International Journal of Dermatology, 2016, 55, 599-607.	1.0	11
304	Vaccine availability in the US: problems and solutions. Nature Immunology, 2004, 5, 1195-1198.	14.5	10
305	Identification of HLA-DRB1-bound self-peptides following measles virus infection. Journal of Immunological Methods, 2005, 297, 153-167.	1.4	10
306	Severity of Childhood Asthma and Human Leukocyte Antigens Type. Journal of Asthma, 2007, 44, 163-168.	1.7	10

#	Article	IF	Citations
307	Protecting Patients from HarmLegislating Vaccinations for Healthcare Workers. American Journal of Preventive Medicine, 2007, 32, 544-546.	3.0	10
308	A Qualitative and Quantitative Comparison of Two Rubella Virus-Specific IgG Antibody Immunoassays. Viral Immunology, 2010, 23, 353-357.	1.3	10
309	Another coronavirus, another epidemic, another warning. Vaccine, 2020, 38, v-vi.	3.8	10
310	Vaccine Safety: Injecting a Dose of Common Sense. Mayo Clinic Proceedings, 2000, 75, 135-139.	3.0	9
311	Differential HLA Gene Expression in Measles Vaccine Seropositive and Seronegative Subjects: A Pilot Study. Scandinavian Journal of Infectious Diseases, 2003, 35, 332-336.	1.5	9
312	Intranasal Cold-Adapted Influenza Virus Vaccine Combined with Inactivated Influenza Virus Vaccines. Drugs and Aging, 2004, 21, 349-359.	2.7	9
313	Immune Activation at Effector and Gene Expression Levels After Measles Vaccination in Healthy Individuals: A Pilot Study. Human Immunology, 2005, 66, 1125-1136.	2.4	9
314	Plagiarism, self-plagiarism, scientific misconduct, and VACCINE: Protecting the science and the public. Vaccine, 2012, 30, 7131-7133.	3.8	9
315	The nursing profession and patient safety and healthcare provider influenza immunization: The puzzling stance of the American Nursing Association. Vaccine, 2012, 30, 1753-1755.	3.8	9
316	Measles vaccination in health care personnel: Mandates, ethics, and patient safety. Vaccine, 2012, 30, 4407-4408.	3.8	9
317	Smallpox and vaccinia. , 2013, , 718-745.		9
318	Identification of naturally processed Zika virus peptides by mass spectrometry and validation of memory T cell recall responses in Zika convalescent subjects. PLoS ONE, 2021, 16, e0252198.	2.5	9
319	Proteomic assessment of humoral immune responses in smallpox vaccine recipients. Vaccine, 2022, 40, 789-797.	3.8	9
320	Valuing Influenza Vaccine: Medical, Economic, and Social Benefits. Clinical Infectious Diseases, 2009, 48, 299-301.	5.8	8
321	The Imperative of Influenza Vaccines for Elderly Individualsâ€"An Evolving Story. Journal of Infectious Diseases, 2009, 200, 161-163.	4.0	8
322	The social, political, ethical, and economic aspects of biodefense vaccines. Vaccine, 2009, 27, D23-D27.	3.8	8
323	Why not destroy the remaining smallpox virus stocks?. Vaccine, 2011, 29, 2823-2824.	3.8	8
324	Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using TaqmanÂ® Low density immune arrays. Journal of Immunological Methods, 2011, 366, 69-78.	1.4	8

#	Article	IF	Citations
325	Influenza vaccine and Guillain-BarrÃ© syndrome: making informed decisions. Lancet, The, 2013, 381, 1437-1439.	13.7	8
326	The Integration of Epistasis Network and Functional Interactions in a GWAS Implicates RXR Pathway Genes in the Immune Response to Smallpox Vaccine. PLoS ONE, 2016, 11, e0158016.	2.5	8
327	Readability of Participant Informed Consent Forms and Informational Documents. Mayo Clinic Proceedings, 2021, 96, 2095-2101.	3.0	8
328	Influence of HLA-DRB1 alleles on lymphoproliferative responses to a naturally processed and presented measles virus phosphoprotein in measles immunized individuals. Human Immunology, 2004, 65, 209-217.	2.4	7
329	Assessing participation bias in a population-based study of measles-mumps-rubella vaccine immunity in children and adolescents aged 12?18. Paediatric and Perinatal Epidemiology, 2007, 21, 376-384.	1.7	7
330	Thirty years after smallpox: Celebration and sobering thoughts. Vaccine, 2010, 28, 4013-4014.	3.8	7
331	Immunization guidelines in the United States: New vaccines and new recommendations for children, adolescents, and adults. Vaccine, 2013, 31, 4689-4693.	3.8	7
332	Durability of humoral immune responses to rubella following MMR vaccination. Vaccine, 2020, 38, 8185-8193.	3.8	7
333	Adolescent Hepatitis B Immunization: Making It Simpler. Pediatrics, 2001, 107, 771-772.	2.1	7
334	Vaccine safety in an era of novel vaccines: a proposed research agenda. Nature Reviews Immunology, 2022, 22, 203-204.	22.7	7
335	The role of sodium bisulfite in the 1996â€"1997 USA influenza vaccine recall. Vaccine, 1998, 16, 1865-1868.	3.8	6
336	Current paradoxes and changing paradigms in vaccinology. Vaccine, 1999, 17, 1605-1611.	3.8	6
337	Comparison of Fingerstick Versus Venipuncture for Antibody Testing of Measles and Rubella. Scandinavian Journal of Infectious Diseases, 2003, 35, 107-109.	1.5	6
338	The overall safety profile of currently available vaccines directed against infectious diseases. Expert Opinion on Drug Safety, 2003, 2, 215-223.	2.4	6
339	Methodologic reporting requirements for clinical trials: Advancing the science today and tomorrow. Vaccine, 2011, 29, 5087-5089.	3.8	6
340	The Jenner Society and the Edward Jenner Museum: Tributes to a physician-scientist. Vaccine, 2011, 29, D152-D154.	3.8	6
341	What is excellent science and how does it relate to what we publish in vaccine?. Vaccine, 2013, 31, 5147-5148.	3.8	6
342	Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology. PLoS ONE, 2017, 12, e0188149.	2.5	6

#	Article	IF	Citations
343	Detection and Quantification of Influenza A/H1N1 Virus-Specific Memory B Cells in Human PBMCs Using ELISpot Assay. Methods in Molecular Biology, 2018, 1808, 221-236.	0.9	6
344	Associations between measles antibody levels and the protein structure of class II human leukocyte antigens. Human Immunology, 2003, 64, 696-707.	2.4	5
345	Hepatitis B immunization after liver transplantation: What is the answer?. Liver Transplantation, 2005, 11, 1181-1183.	2.4	5
346	Preserving Civility in Vaccine Policy Discourse. JAMA - Journal of the American Medical Association, 2019, 322, 209.	7.4	5
347	Effective and equitable influenza vaccine coverage in older and vulnerable adults: The need for evidence-based innovation and transformation. Vaccine, 2019, 37, 2167-2170.	3.8	5
348	The economics of global COVID vaccine administration during a pandemic â€“ Why continue skin alcohol preparation as a costly but ineffective practice?. Vaccine, 2021, 39, 1175-1177.	3.8	5
349	Comparative assessment of allergic reactions to COVIDâ€19 vaccines in Europe and the United States. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1630-1633.	5.7	5
350	Readability of COVID-19 vaccine information for the general public. Vaccine, 2022, 40, 3466-3469.	3.8	5
351	A novel method for assigning TAP1 genotype using restriction enzyme plus PASA methodology. Human Immunology, 1999, 60, 1289-1292.	2.4	4
352	High frequency of HLA-Aâˆ—0103 allele in a Somali population. Human Immunology, 2001, 62, 197-200.	2.4	4
353	Health care worker pertussis immunization requirements and patient safety. American Journal of Infection Control, 2008, 36, 390-391.	2.3	4
354	The process of continuous journal improvement: New author guidelines for statistical and analytical reporting in VACCINE. Vaccine, 2012, 30, 2915-2917.	3.8	4
355	Vaccine history: The past as prelude to the future. Vaccine, 2012, 30, 5299-5301.	3.8	4
356	Are Impact Factors corrupting truth and utility in biomedical research?. Vaccine, 2013, 31, 6041-6042.	3.8	4
357	ImmuneRegulation: a web-based tool for identifying human immune regulatory elements. Nucleic Acids Research, 2019, 47, W142-W150.	14.5	4
358	Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine. Vaccine, 2020, 38, 7897-7904.	3.8	4
359	Vaccines, masks, distancing and credibility: An urgent warning for pandemic management. Vaccine, 2021, 39, 1173-1174.	3.8	4
360	Pharmacogenomics and Vaccine Development. Clinical Pharmacology and Therapeutics, 2021, 110, 546-548.	4.7	4

#	Article	IF	Citations
361	Immunization Guidelines for Adult Patients: An Annual Update and a Challenge. Annals of Internal Medicine, 2009, 150, 53.	3.9	4
362	Effect of Differing Immunization Policies on Circulating Measles Antibody Levels in US and Canadian Children. Mayo Clinic Proceedings, 2002, 77, 446-452.	3.0	3
363	Health Care Workers and Influenza Vaccine: First Do No Harm Then Do the Right Thing. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 637-638.	1.5	3
364	A Parent-Driven, Computer-Based Vaccine Information System: Addressing Variability in Information Needs for the Varicella Vaccine. Mayo Clinic Proceedings, 2005, 80, 187-192.	3.0	3
365	From Science II to Vaccinology II: A new epistemology. Vaccine, 2011, 29, 1527-1528.	3.8	3
366	Methods in vaccine effectiveness and safety studies: A critical need for vaccine confidence. Vaccine, 2011, 29, 9573-9574.	3.8	3
367	SARS-CoV-2 Infections: An ACE in the Hole and Systems Biology Studiesâ€"a Research Agenda. Mayo Clinic Proceedings, 2020, 95, 1838-1841.	3.0	3
368	Transcriptional signatures associated with rubella virusâ€specific humoral immunity after a third dose of MMR vaccine in women of childbearing age. European Journal of Immunology, 2021, 51, 1824-1838.	2.9	3
369	Effect of Differing Immunization Policies on Circulating Measles Antibody Levels in US and Canadian Children. Mayo Clinic Proceedings, 2002, 77, 446-452.	3.0	2
370	The Edward Jenner Society: A new academic society for vaccinologists. Vaccine, 2010, 28, 4439.	3.8	2
371	Response surface methodology to determine optimal measles-specific cytokine responses in human peripheral blood mononuclear cells. Journal of Immunological Methods, 2012, 382, 220-223.	1.4	2
372	United Nations mercury treaty jeopardizes vaccine protection of the world's most vulnerable children. Vaccine, 2013, 31, 1357-1358.	3.8	2
373	Health Care Reform and Influenza Immunization. Workplace Health and Safety, 2013, 61, 193-195.	1.4	2
374	Antibody Dynamics, Seroreversion, and Persistence After Severe Acute Respiratory Syndrome Coronavirus 2: Another Answer. Clinical Infectious Diseases, 2021, 73, 2163-2165.	5.8	2
375	Influenza Vaccination and the Elderly. Drugs and Aging, 2008, 25, 179-186.	2.7	1
376	Putting the puzzle pieces together: the dynamic landscape of influenza vaccine and policy. Vaccine, 2010, 28, D1-D2.	3.8	1
377	HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: A pilot study. Vaccine, 2012, 30, 6628-6631.	3.8	1
378	New influenza vaccines: Promises, perils, and pitfalls. Vaccine, 2012, 30, 983-984.	3.8	1

#	Article	IF	Citations
379	Edward Jenner and the discovery of vaccinationâ€"An appeal for the Edward Jenner Museum. Vaccine, 2013, 31, 4933-4934.	3.8	1
380	Visual Vaccinology â€" The Importance of Visual Communication. Vaccine, 2013, 31, 4465.	3.8	1
381	The Importance of Peer Review. Vaccine, 2013, 31, 567-583.	3.8	1
382	Answering the call for educating the new generation of vaccinologists â€" A new European Erasmus+ Joint Master degree in vaccinology. Vaccine, 2015, 33, 6135-6136.	3.8	1
383	Celebrating the ACIP at 50. Vaccine, 2015, 33, 403-404.	3.8	1
384	Immunoglobulin GM and KM genes and measles vaccine-induced humoral immunity. Vaccine, 2017, 35, 5444-5447.	3.8	1
385	Vaccine Use in Immunocompromised Adults. , 2019, , 139-162.		1
386	Detection of SARS-CoV-2 peptide-specific antibodies in Syrian hamster serum by ELISA. Journal of Immunological Methods, 2022, 505, 113275.	1.4	1
387	Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine, 2003, 22, 1914-1914.	3.8	0
388	VACCINE in the 21st century: What's next?. Vaccine, 2010, 28, 1437.	3.8	0
389	The day that Jack diedâ˜†. Vaccine, 2011, 29, 2227-2228.	3.8	0
390	Response to Dr. Norman W. Baylor's Letter to the Editor entitled: â€œPerspective of the U.S. Food and Drug Administration on Concomitant Administration of Zostavax and Pneumovaxâ€. Vaccine, 2011, 29, 8772.	3.8	0
391	Editor-in-Chief response. Vaccine, 2011, 29, 7588.	3.8	0
392	Next generation personalized animals as an enabling technology in personalized vaccinology. Vaccine, 2013, 31, 725-727.	3.8	0
393	Health Care Reform and Influenza Immunization. Workplace Health and Safety, 2013, 61, 193-195.	1.4	0
394	Submission of articles to Vaccine: A fast and fair peer review process. Vaccine, 2013, 31, 3207-3208.	3.8	0
395	Vaccinology in the 21st centuryâ€"The 10th Annual Vaccine Congress. Vaccine, 2017, 35, 4451-4452.	3.8	0
396	The 2019 immunization schedules for children, adolescents and adults. Whatâ€™s New?. Vaccine, 2019, 37, 3379-3380.	3.8	0

#	Article	IF	Citations
397	Zika Vaccines. , 2019, , 75-88.		0
398	Expression of concern: â€œCould the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular groupÂXÂoutbreaks in Africa?â€•and â€œBactericidal antibody against a representative epidemiological meningococcal serogroupâ€• Vaccine, 2020, 38, 5577.	3.8	0
399	Introduction to Perspectives. Vaccine, 2020, 38, 6347.	3.8	0
400	The contributions of William Money MRCS to smallpox vaccination and control â€" A little-known story. Vaccine, 2021, 39, 4914-4919.	3.8	0
401	Immunization of Healthcare Personnel: A Continuing Issue. Vaccine: X, 2022, 11, 100169.	2.1	0